Susanne P Stoof1, Gerwin D Rodenburg2, Mirjam J Knol3, Lidewij W Rümke2, Sandra Bovenkerk4, Guy A M Berbers3, Lodewijk Spanjaard5, Arie van der Ende5, Elisabeth A M Sanders1. 1. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht. 2. Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht. 3. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven. 4. Department of Medical Microbiology. 5. Department of Medical Microbiology Netherlands Reference Laboratory for Bacterial Meningitis, Center for Infection and Immunity Amsterdam, Academic Medical Center, The Netherlands.
Abstract
BACKGROUND: Several countries consider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for adolescents. Representative information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-effectiveness of vaccination. Information on the relation between infecting meningococcal clonal complex (CC), disease course and outcome of IMD is scarce. METHODS: A retrospective study using Dutch surveillance data on IMD from June 1999 to June 2011. Clinical information was retrieved from hospital records. The effect of age, comorbidity, clinical manifestation, serogroup, and CC on disease course and outcome was assessed in multivariable analyses. Meningococcal CCs were assessed by multilocus sequence typing. RESULTS: Clinical information was retrieved for 879 IMD cases: 48% of patients presented with meningitis, 17% with septic shock, and 22% with septic shock plus meningitis. Development of septic shock was not related to CC or serogroup. Median (interquartile range) duration of hospital admission was 10 (8-13) days. Intensive care unit admittance (38%) was higher for patients aged ≥10 years and patients with septic shock (P-values ≤.001). Case-fatality rate (8%) and development of sequelae (29%) was dependent on age and clinical manifestation (P-values ≤.001) and not affected by comorbidity, CC, or serogroup. CONCLUSIONS: IMD still coincides with a considerable disease burden and mortality. Disease course and outcome depend mainly on age and clinical manifestation and less on meningococcal CC or serogroup.
BACKGROUND: Several countries consider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for adolescents. Representative information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-effectiveness of vaccination. Information on the relation between infecting meningococcal clonal complex (CC), disease course and outcome of IMD is scarce. METHODS: A retrospective study using Dutch surveillance data on IMD from June 1999 to June 2011. Clinical information was retrieved from hospital records. The effect of age, comorbidity, clinical manifestation, serogroup, and CC on disease course and outcome was assessed in multivariable analyses. Meningococcal CCs were assessed by multilocus sequence typing. RESULTS: Clinical information was retrieved for 879 IMD cases: 48% of patients presented with meningitis, 17% with septic shock, and 22% with septic shock plus meningitis. Development of septic shock was not related to CC or serogroup. Median (interquartile range) duration of hospital admission was 10 (8-13) days. Intensive care unit admittance (38%) was higher for patients aged ≥10 years and patients with septic shock (P-values ≤.001). Case-fatality rate (8%) and development of sequelae (29%) was dependent on age and clinical manifestation (P-values ≤.001) and not affected by comorbidity, CC, or serogroup. CONCLUSIONS: IMD still coincides with a considerable disease burden and mortality. Disease course and outcome depend mainly on age and clinical manifestation and less on meningococcal CC or serogroup.
Authors: Noortje de Haan; Navin P Boeddha; Ebru Ekinci; Karli R Reiding; Marieke Emonts; Jan A Hazelzet; Manfred Wuhrer; Gertjan J Driessen Journal: MBio Date: 2018-06-19 Impact factor: 7.867
Authors: Anna D Loenenbach; Arie van der Ende; Hester E de Melker; Elisabeth A M Sanders; Mirjam J Knol Journal: Clin Infect Dis Date: 2020-05-06 Impact factor: 9.079
Authors: Marieke van der Heiden; Annemieke M H Boots; Axel A Bonacic Marinovic; Lia G H de Rond; Marjan van Maurik; Irina Tcherniaeva; Guy A M Berbers; Anne-Marie Buisman Journal: Front Immunol Date: 2017-07-19 Impact factor: 7.561
Authors: Diederik A H Brandwagt; Arie van der Ende; Wilhelmina L M Ruijs; Hester E de Melker; Mirjam J Knol Journal: BMC Infect Dis Date: 2019-10-17 Impact factor: 3.090